A joint panel of FDA advisors will meet next month to discuss the cardiovascular (CV) thromboembolic risks of non-steroidal anti-inflammatory drugs (NSAIDs). The joint meeting of the agency’s Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee will is scheduled for Feb. 10-11 at the FDA’s White Oak, Md., campus.
A 2005 meeting of advisors concluded that both COX-2 selective NSAIDs and nonselective NSAIDs held potential risks but no decision was reached as to which held the greater threat.
The February meeting will discuss literature published since, with a specific focus on:
Some of the NSAIDs in question are Pfizer’s Bextra (valdecoxib) and Celebrex (celecoxib). — Lena Freund
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.